Project Grant R01HL180762
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $779K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $108,950 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoplatforms for co-delivery of drugs and genes to protect lung endothelium from neonatal and pediatric lung injury. The recipient will optimize nanoparticle formulations for stability, safety, and endothelial targeting in neonatal lungs, characterizing physicochemical properties that influence targeting...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $726,242 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the cellular and molecular role of GATA4 in bicuspid aortic valve disease. The project, R01HL183091, runs through May 31, 2030, with place of performance in Tucson, Arizona. The award funds three research aims. Aim 1 comprehensively characterizes a GATA4S379G mouse model of bicuspid aortic valve disease,...
- The National Heart, Lung, and Blood Institute awarded New York University $1,692,126 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA upregulated in atherosclerotic cardiovascular disease. The research will map CHROMR-protein interfaces and design steric-blocking oligonucleotides to selectively disrupt the CHROMR-IRF2BP2 interaction, decoupling its pro-inflammatory...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded New York University $763,960 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which long non-coding RNA IRF1-AS1 and its mouse ortholog GM12216 regulate atherosclerotic cardiovascular disease. The research will examine how IRF1-AS1 coordinates expression of protein-coding genes including the transcriptional regulator IRF1 in myeloid cells to drive atherogenesis,...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $748,677 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle delivery systems targeting lung endothelial cell repair in pediatric acute respiratory distress syndrome (ARDS). The research addresses the lack of innovative molecular approaches to pediatric ARDS management by engineering lung endothelial cell-specific nanoparticle carriers capable of delivering...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanosensitive signaling mechanisms that support endothelial cell resilience in the context of cardiovascular disease treatment. The research elucidates a mechanosensitive signaling domain in endothelial cells and tests how TRPV4-mediated calcium signaling promotes vascular resilience....